Recent Updates
Recently added Catalysts
GERN Negative Sentiment Score: 35/100

GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Geron Corporation on behalf of long-term stockholders after a class action complaint was filed. The lawsuit claims that Geron misled investors about the commercial prospects for its drug, Rytelo, during a specified class period. Allegations suggest the company's board may not have adequately disclosed risks related to the drug's monitoring requirements and competitive pressures. The law firm is actively seeking long-term stockholder input regarding these issues.

Market Sentiment Analysis

CONCERNS & RISKS

  • Geron Corporation faces a class action complaint alleging breaches of fiduciary duties.
  • The complaint suggests potentially misleading information was provided to investors regarding Rytelo's launch and growth projections.
  • There are concerns over the risks tied to Rytelo's weekly monitoring requirement and competition affecting its sales.

Full Press Release Details

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigation concerns whether the board of directors of Geron have breached their fiduciary duties to the company.
The Complaint alleges that throughout the Class Period, Defendants provided investors with material information concerning Defendants' expectations for the launch and growth potential of Rytelo (imetelstat). The Complaint alleges that Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug's sales.
If you are a long-term stockholder of Geron, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the focus of the investigation by Bragar Eagel & Squire?

The investigation examines potential claims against Geron Corporation regarding breaches of fiduciary duties.

What is the Class Period mentioned in the Geron complaint?

The Class Period is from February 28, 2024, to February 25, 2025.

What drug is at the center of the Geron Corporation investigation?

The drug involved is Rytelo (imetelstat), which targets ESA ineligible patients.

How can long-term stockholders contact the law firm?

Stockholders can reach out by email, phone, or via a contact form on their website.

Is there a cost for contacting Bragar Eagel & Squire about the claims?

There is no cost or obligation for contacting the firm regarding the claims.

Last updated: May 16, 2025